莫西沙星杂质Ⅳ | 866954-86-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 莫西沙星杂质Ⅳ
• 英文名称: ethyl (2Z)-3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate
• 英文别名: 2-(2,4,5-Trifluoro-3-methoxybenzoyl)-3-ethoxyacrylic Acid Ethyl Ester；ethyl (Z)-3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)prop-2-enoate
• CAS: 866954-86-1
• 化学式: C₁₅H₁₅F₃O₅
• 分子量: 332.276
• InChiKey: ZIMIAPVHHUISPY-CLFYSBASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  莫西沙星杂质Ⅳ 在 potassium carbonate 、 三乙胺 作用下， 以 二甲基亚砜 、 乙酸乙酯 、 丙酮 为溶剂， 反应 31.17h， 生成
  参考文献：
  名称：

  A Prodrug Approach toward the Development of Water Soluble Fluoroquinolones and Structure−Activity Relationships of Quinoline-3-carboxylic Acids

  摘要：

  A fluoroquinolone prodrug, PA2808, was prepared and shown to convert to the highly active parent drug PA2789. In vitro and in vivo activation of PA2808 by alkaline phosphatase was demonstrated using disk diffusion and rat lung infection models. The water solubility of PA2808 showed a marked increase compared to PA2789 over a pH range suitable for aerosol drug delivery. A total of 48 analogues based on PA2789 were prepared and screened against a panel of Gram-positive and Gram-negative pathogens. Incorporating a cyclopropane-fused pyrrolidine (amine g) at C-7 resulted in some of the most active analogues.

  DOI：

  10.1021/jm0497895
• 作为产物：
  描述：

  3-甲氧基-2,4,5-三氟苯甲酸 在 草酰氯 、 乙酸酐 、 三乙胺 、 N,N-二甲基甲酰胺 、 magnesium chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 22.0h， 生成 莫西沙星杂质Ⅳ
  参考文献：
  名称：

  A Prodrug Approach toward the Development of Water Soluble Fluoroquinolones and Structure−Activity Relationships of Quinoline-3-carboxylic Acids

  摘要：

  A fluoroquinolone prodrug, PA2808, was prepared and shown to convert to the highly active parent drug PA2789. In vitro and in vivo activation of PA2808 by alkaline phosphatase was demonstrated using disk diffusion and rat lung infection models. The water solubility of PA2808 showed a marked increase compared to PA2789 over a pH range suitable for aerosol drug delivery. A total of 48 analogues based on PA2789 were prepared and screened against a panel of Gram-positive and Gram-negative pathogens. Incorporating a cyclopropane-fused pyrrolidine (amine g) at C-7 resulted in some of the most active analogues.

  DOI：

  10.1021/jm0497895

文献信息

• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• Aminoquinolones as GSK-3 inhibitors
  申请人：Cociorva Oana

  公开号：US20070254866A1

  公开（公告）日：2007-11-01

  Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.

  本文提供了氨基喹啉及其药用可接受的衍生物。在某些实施例中，本文提供了用于治疗、预防或改善GSK-3介导疾病的化合物、组合物和方法。
• Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions
  申请人：Khire Uday

  公开号：US20070213339A1

  公开（公告）日：2007-09-13

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R 1 , R 4 , R 10 , R 11 , R 19 , and R 20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择性地取代的苯基，吡啶基或嘧啶基，取代基R1，R4，R10，R11，R19和R20如规范中所定义，以及包含它们的制药组合物和在治疗增生性疾病如癌症中使用它们的方法。
• 1,4-Dihydro-4-oxo-3-quinolone derivatives as selectively toxic mammalian antibacterial agents
  申请人：PFIZER INC.

  公开号：EP0421668A2

  公开（公告）日：1991-04-10

  Compounds of the formula and the pharmaceutically acceptable salts thereof, wherein Q, X and R are as defined below. The compounds of formula I are broad spectrum mammalian antibacterial agents and exhibit favorable selectivity against procaryotic cells.

  式中的化合物 及其药学上可接受的盐类，其中 Q、X 和 R 如下文所定义。式 I 的化合物是广谱哺乳动物抗菌剂，对原核细胞具有良好的选择性。
• Aminoquinolones as GSK-3 Inhibitors
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP2383271A1

  公开（公告）日：2011-11-02

  Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.

  本文提供的是氨基喹诺酮及其药学上可接受的衍生物。在某些实施方案中，本文提供了用于治疗、预防或改善 GSK-3 介导的疾病的化合物、组合物和方法。